• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Multimodal treatment of aggressive forms of breast cancer.
J Med Life. 2014 Sep 15;7(3):415-20. Epub 2014 Sep 25.
2
The role of immunohistochemical tests in multimodal treatment of the aggressive forms of breast cancer.免疫组织化学检测在侵袭性乳腺癌多模式治疗中的作用。
J Med Life. 2014;7 Spec No. 2(Spec Iss 2):58-64.
3
Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.Alliance A011801(compassHER2 RD):新辅助治疗后 T-DM1 联合或不联合 tucatinib/安慰剂治疗残留 HER2 阳性浸润性乳腺癌患者。
Future Oncol. 2021 Dec;17(34):4665-4676. doi: 10.2217/fon-2021-0753. Epub 2021 Oct 12.
4
A study on clinico-pathological assessment of response to neoadjuvant chemotherapy in breast carcinoma.一项关于乳腺癌新辅助化疗反应的临床病理评估研究。
J Cancer Res Ther. 2020 Oct-Dec;16(6):1419-1425. doi: 10.4103/jcrt.JCRT_295_19.
5
New treatment sequence protocol to reconstruct locally advanced breast cancer.重建局部晚期乳腺癌的新治疗序列方案。
ANZ J Surg. 2013 Sep;83(9):630-5. doi: 10.1111/ans.12110. Epub 2013 Mar 15.
6
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer.乳腺癌治疗专家组(BCTEG)圆桌讨论:人表皮生长因子受体2(HER2)阳性乳腺癌的临床进展与实践指南
Clin Breast Cancer. 2020 Jun;20(3):e251-e260. doi: 10.1016/j.clbc.2019.08.001. Epub 2019 Aug 21.
7
Risk factors for breast cancer-related lymphedema: correlation with docetaxel administration.乳腺癌相关淋巴水肿的风险因素:与多西紫杉醇给药的相关性。
Breast Cancer. 2020 Sep;27(5):929-937. doi: 10.1007/s12282-020-01088-x. Epub 2020 Apr 8.
8
UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer.UNICANCER-PEGASE 07 研究:一项评价新辅助剂量密集化疗后接受多西紫杉醇-5FU 方案辅助治疗炎性乳腺癌的随机 III 期临床试验。
Ann Oncol. 2015 Aug;26(8):1692-7. doi: 10.1093/annonc/mdv216. Epub 2015 May 5.
9
Role of endocrine responsiveness and HER2/neu overexpression in inflammatory breast cancer treated with multimodality preoperative therapy.内分泌反应性和HER2/neu过表达在多模式术前治疗的炎性乳腺癌中的作用。
Breast J. 2008 Sep-Oct;14(5):435-41. doi: 10.1111/j.1524-4741.2008.00619.x.
10
Clinicopathologic Factors Associated With Response to Neoadjuvant Anti-HER2-Directed Chemotherapy in HER2-Positive Breast Cancer.与曲妥珠单抗为基础的新辅助化疗治疗人表皮生长因子受体 2 阳性乳腺癌疗效相关的临床病理因素。
Clin Breast Cancer. 2020 Feb;20(1):19-24. doi: 10.1016/j.clbc.2019.09.003. Epub 2019 Sep 18.

引用本文的文献

1
Synchronous Primary Metastatic Infra-Mammary Accessory Breast Cancer and Ipsilateral Breast Cancer: An Extremely Rare Case Report.同步原发性乳腺下副乳腺癌和同侧乳腺癌:1例极其罕见的病例报告
Diagnostics (Basel). 2024 Nov 29;14(23):2699. doi: 10.3390/diagnostics14232699.
2
Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable.原发性及放疗相关乳腺血管肉瘤多模式治疗的临床结果:可实现长期生存。
Cancers (Basel). 2021 Jul 29;13(15):3814. doi: 10.3390/cancers13153814.

本文引用的文献

1
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges.美国临床肿瘤学会临床实践指南:机遇与挑战
J Clin Oncol. 2008 Aug 20;26(24):4022-6. doi: 10.1200/JCO.2008.17.7139.
2
Core-cutting needle biopsy for the diagnosis of breast cancer.用于乳腺癌诊断的芯针活检。
Am J Surg. 1982 May;143(5):622-3. doi: 10.1016/0002-9610(82)90179-9.

Multimodal treatment of aggressive forms of breast cancer.

作者信息

Mihai D, Voiculescu S, Cristian D, Constantinescu F, Popa E, Burcos T

机构信息

Surgery Clinic, "Coltea" Hospital, Bucharest.

出版信息

J Med Life. 2014 Sep 15;7(3):415-20. Epub 2014 Sep 25.

PMID:25408768
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4233452/
Abstract

UNLABELLED

Aggressive breast cancer is an invasive form with G3, G4 differentiation degree, the absence of receptors for estrogen and progesterone and the absence or presence of HER2 (+ or 3+) gene. The final diagnosis is established by cumulating the clinical, paraclinical, histopathological and immunohistochemical diagnosis.

MATERIAL AND METHOD

84 out of 268 aggressive breast cancer cases were presented in the study, which were operated in October 2011-September 2013. The inclusion and exclusion criteria are exposed in the study lot and the treatment schemes.

RESULTS

For the study lot (lot A made up of 36 cases, lot B made up of 41 cases, lot C made up of 7 cases) the distribution was presented on age groups, histopathological and immunohistochemical classification, etiologic factors, type of surgery, postoperative staging and complications.

CONCLUSIONS

The treatment of aggressive breast cancer depends on the level of the aggressiveness of the disease, the biologic status and the age that imposes the order of chemotherapy, radiotherapy, surgical treatment and target therapy.

摘要